⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874788 | 0.63 | — | — | |
| SCHEMBL1429616 | 0.58 | — | — | |
| SCHEMBL29545 | 0.57 | — | — | |
| SCHEMBL389120 | 0.57 | — | — | |
| SCHEMBL8677458 | 0.55 | — | — | |
| SCHEMBL15161789 | 0.53 | — | — | |
| SCHEMBL2655903 | 0.53 | — | — | |
| SCHEMBL7947882 | 0.53 | — | — | |
| SCHEMBL19927005 | 0.53 | — | — | |
| Hydrochloric Acid SCHEMBL15967490 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511862-A | Improved process for the preparation of copolymer-1 | MOMENTA PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | CN | claimed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114555556-B | Process for preparing CFTR modulators | 弗特克斯药品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115427081-A | Drug antibody conjugates | 法马马有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113226377-B | Antibody drug conjugates comprising an eltrinastine derivative | 法马马有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114751920-A | Antitumor compounds | 法马马有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114736219-A | Antitumor compounds | 法马马有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114555556-A | Methods of making CFTR modulators | 弗特克斯药品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113226377-A | Antibody drug conjugates comprising an eltrinastine derivative | 法马马有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113166102-A | Anticancer compounds | 法马马有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110621678-A | Antitumor compounds | 法马马有限公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-101932592-B | Antitumoral compounds | PHARMA MAR SA | 2014-02-26 | — | — | CN | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| CN-101932592-A | Antineoplastic compound | PHARMA MAR SA | 2010-12-29 | — | — | CN | disclosed |
| CN-101511862-A | Improved process for the preparation of copolymer-1 | MOMENTA PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | CN | disclosed |